Blue Fin Capital Inc. Lowers Holdings in Merck & Company, Inc. (MRK)

Blue Fin Capital Inc. decreased its position in shares of Merck & Company, Inc. (NYSE:MRK) by 0.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,113 shares of the company’s stock after selling 175 shares during the period. Merck & makes up approximately 1.2% of Blue Fin Capital Inc.’s holdings, making the stock its 22nd largest holding. Blue Fin Capital Inc.’s holdings in Merck & were worth $1,801,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Perennial Advisors LLC raised its position in Merck & by 10.7% during the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after purchasing an additional 157 shares in the last quarter. Cascade Investment Advisors Inc. raised its position in Merck & by 15.5% during the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after purchasing an additional 232 shares in the last quarter. Vigilant Capital Management LLC raised its position in Merck & by 16.7% during the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after purchasing an additional 250 shares in the last quarter. Solaris Asset Management LLC raised its position in Merck & by 6.3% during the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after purchasing an additional 115 shares in the last quarter. Finally, Harbour Capital Advisors LLC purchased a new stake in Merck & during the first quarter valued at about $127,000. Institutional investors and hedge funds own 72.86% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Blue Fin Capital Inc. Lowers Holdings in Merck & Company, Inc. (MRK)” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/11/01/blue-fin-capital-inc-lowers-holdings-in-merck-company-inc-mrk.html.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at 55.09 on Wednesday. The company has a 50 day moving average price of $63.71 and a 200 day moving average price of $63.55. Merck & Company, Inc. has a 1-year low of $54.41 and a 1-year high of $66.80. The company has a market capitalization of $150.25 billion, a PE ratio of 29.83 and a beta of 0.80.

Merck & (NYSE:MRK) last posted its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 26.82%. The company had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. During the same period in the prior year, the company posted $1.07 EPS. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis. Equities analysts predict that Merck & Company, Inc. will post $3.92 EPS for the current fiscal year.

MRK has been the topic of several analyst reports. UBS AG lifted their price objective on Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies set a $70.00 price objective on Merck & and gave the stock a “buy” rating in a report on Saturday, July 29th. BMO Capital Markets reiterated a “buy” rating and issued a $72.00 price objective on shares of Merck & in a report on Friday, September 8th. Citigroup Inc. upgraded Merck & from a “neutral” rating to a “buy” rating and set a $72.00 price objective on the stock in a report on Wednesday, October 18th. Finally, J P Morgan Chase & Co set a $70.00 price objective on Merck & and gave the stock a “buy” rating in a report on Sunday. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $67.07.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit